[{"Assets_0_Q3_USD":1046999000.0,"CommonStockSharesOutstanding_0_Q3_shares":46830589.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-158893000.0,"NetIncomeLoss_1_Q3_USD":-122918000.0,"NetIncomeLoss_3_Q3_USD":-214494000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":46706770.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":45866676.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":46706770.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":45866676.0,"StockholdersEquity_0_Q3_USD":988505000.0,"Ticker":"SAGE","CIK":"1597553","name":"SAGE THERAPEUTICS, INC.","OfficialName":"Sage Therapeutics Inc. Common Stock","form":"10-Q","period":"20180930","fy":"2018.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"2034401653.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20181106"}]